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The following Investment Committee paper focuses on a proposal for a leveraged buyout on Elekta AB, a key player in the global radiotherapy market which sells in more 
than 120 countries. In fact, this paper develops a set of value creation strategies, with special focus on Buy-and-Build, based on company and market analysis, reflecting 
those strategies in a detailed operating model. Subsequently, a capital structure is suggested by assessing past buyout transactions in the healthcare sector and by 
leveraging the bank case. Finally, the exit returns are estimated complying with industry threshold and a range of exit strategies are analyzed. 
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Program. We, hereby, pledge on our honor that the work presented is ours and that none dishonest method was used in its execution. Furthermore, we declare that this 
Work Project is intended to be used for academic purposes only. Therefore, we restrain ourselves from taking any responsibility from the wrong usage of the content 
presented, namely any investment or legal action taken grounded on it. 
This Work Project was developed using publicly available data and information provided by the company (i.e., annual reports, investor relations, presentations, etc.). The
sources of the information are disclosed when appropriated.
This Work Project is divided into three complementary parts. For an integral analysis of the Work Project please see the remaining two parts named “APAC’s influence in
the future of Radiotherapy Market” and “Mitigation of Structural Differences in Cancer Treatment”
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Elekta AB is a Swedish manufacturer of radiotherapy
medical equipment. Its products and aftermarket
services are sold to both public and private sector;
Its product portfolio consists of linear accelerators,
magnetic resonance imaging linear accelerators
(MR-Linacs), brachytherapy, oncology informatic
solutions (OIS) and neurosolutions;
Elekta provides a range of quality services that
include maintenance, updates, training, among
others;
With an emphasis in customization, Elekta has been
one of the main leaders in the radiotherapy market.
COMPANY PROFILE
Elekta seems to be an exciting investment opportunity yielding an investors’ return of 3.14x
DEAL RATIONALE
VALUE CREATION & EXIT AND RETURNS
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INDUSTRY PROFILE
Elekta is distinguished by its efficiency and has reached
a leading position in emerging markets
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
Free Cash Flow generated by the company is robust
and has been stable over the past few years
Strategic value-adding acquisitions allowed Elekta to
become a key player in radiotherapy market
Acquisition history
Sizeable and Growing Market
Optimistic industry growth prospects, since cancer




Radiotherapy is one of the main types of cancer
treatment. With cancer incidence expected to
increase until 2040, significant investments have
been made in the oncology market;
Accordingly, the radiotherapy market is expected to
increase at a CAGR of 7.3% until 2029, from a $6.6B
value in 2019;
This growth will be mainly driven by innovations in the
sector (namely MR-Linacs and OIS), and the
increasing demand for radiotherapy, as 60% of
cancer patients are expected to need it.
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o It is expected that the increase in revenues and the
improvement of EBITDA margin, will create SEK
50,629M of value;
o With the deleveraging effect, the investment will
generate SEK 57,500M of value.
o The fund will generate a combined return of 3.45x in
five years (IRR of 28.07%);
o Institutional investors and managers will have
returns of 3.14x and 136.1x respectively.
Financials 2020 2021F 2022F 2023F 2024F 2025F
Organic Sales 14,601 14,722 19,506 22,571 24,214 26,390
% growth - 1% 32% 16% 7% 9%
Org EBITDA 2,921 3,088 4,170 4,814 5,280 5,886
Inorg Sales N/A 0 3,134 4,839 5,584 6,018
% growth - - - 54% 15% 8%
HCG 0 0 3,134 3,302 3,887 4,144
IBA 0 0 0 1,537 1,697 1,874
Inorg EBITDA N/A 0 275 634 784 892
EBITDA 2,921 3,088 4,445 5,449 6,065 6,778
% mg 20% 21% 20% 20% 20% 21%





COMPANY OVERVIEW | PROFILE
o Founded in 1972, its headquarters are located
in Stockholm, Sweden. It has been listed in the
OMX Nordic Exchange since 1994 and currently
employs more than 4,000 people;
o ELEKTA is one of the key players in the global
radiotherapy market, providing radiotherapy
equipment in order to treat different types of
cancer and brain disorders;
o The company sells both to the public and
private sector (hospitals, private clinics) in more
than 120 countries;
o Elekta has a wide range of suppliers – 80%
of sourced products/services come from
approximately 450 suppliers. In some specific
products (MR Linac–Image) there is only one
supplier, which might increase the shortage risk;
o Its position in the value chain is as a medical
equipment manufacturer and software
provider, that has been distinguished by its
innovation and efficiency. It is also known by
customizing their products for each specific
client. The main activities of the production units
are assembly, testing and quality assurance;
COMPANY PROFILE RANGE OF PRODUCTS
Elekta is one of the key players in the global radiotherapy market (radiation therapy & radiosurgery)
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Offers leading solutions in both
radiotherapy treatment and
oncology informatics systems.














PIONEERS IN PRECISION RADIATION MEDICINE
Rank
% Margin
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Sources: Elekta’s Annual Report and Website
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COMPANY OVERVIEW | PRODUCT MIX
Elekta’s diversified product portfolio enables this company to thrive in the radiotherapy market
201720132008 2018
Sources: Elekta’s Annual Report and Website; Investor Presentation 2018
2003
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COMPANY OVERVIEW | GROWTH DRIVERS AND GEOGRAPHICAL BREAKDOWN
Securing improved financial performance as well as operational excellence 
PROFITABILITY DRIVERS
ELEKTA’S ACQUISITION HISTORY
o Elekta’s market share 40%
o Net Sales 31% 
o Solutions 72%
o Services 28%
o Elekta’s market share 43%
o Net Sales 38%
o Solutions 64%
o Services 36%
o Elekta’s market share 21%
o Net Sales 31%
o Solutions 44%
o Services 56%
North and South America EMEA APAC
o Expanding Product Portfolio i.e Brachy Solutions and MRI Linacs
gives access to more potential customers;
o Market need for cost-efficient and digitalized cancer care can be
exploit by Elekta, since it is a key player which provides high-quality
solutions and services;
o Its Precision Radiation Medicine - easier to use, improve patient
experience, increase workflow - can lead to strong customer’s
relationship, increasing clients’ long-term brand loyalty;
o Gross Margin and SG&A margin improvement by increasing the
efficiency in internal processes. Elekta wants to replicate its Harmony
Solution COGS reduction in the other innovative products already
provided, in order to improve its gross margin. By sharing services and
digitalization (remote assistance; remote conferences) it aims to reduce
its SG&A costs (COVID also helped in reducing travel expenses);
NeuromagPhilips Radiation 
Therapy Division 
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Sources: Elekta’s Annual Report 
$20M $75M €365M >SEK 178M
Linear Accelerators;        Oncology Informatics;        Stereotactic Radiosurgery;        Brachytherapy;      MR–Linear Accelerators  
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Market defined by innovative procedures
that will continue to play a major role in
cancer treatment.
EMEA
MARKET OVERVIEW | A BROADER PICTURE OF RADIOTHERAPY
RADIOTHERAPY MARKET AROUND THE WORLD
o The market is steadily growing in Western Europe due to increasing capacity and renovation of
equipment. Private Sector’s role plays an important role, but national programs are the main
responsible for funding cancer treatments, care and research;
o In Eastern Europe there is still a lack of infrastructure, but national services have been developing;
o In Middle East and Africa there is still a considerable lack of resources. However, increasing
awareness of the problems of cancer, the increasing demand in the Middle East and the
emergence of Turkey as a fast-growing market, make MEA a long-term attractive region.
AMERICAS
o North America market is characterized by a prominence of private providers that have
consolidated their position over the years, creating a competitive environment. 60% of North
American patients are treated with radiotherapy and there is increasing demand to renew existent
equipment;
o In South America there is a mix of public and private sector, existing inadequate accessibility to
public services;
o Nevertheless, the emergence of healthcare groups which are investing in radiotherapy clinics and
a need for modernization will drive the market forward in the next years.
APAC
o China is the most important market in the Asia-Pacific region, with the government incentivizing
the expansion of radiotherapy, both in capacity and renewing equipment;
o Japan has one of the biggest growth potential, as 70% of cancer patients do not receive
radiotherapy. Hong-Kong, Australia, Singapore and South Korea are also mature markets with
adequate levels of investment in radiotherapy;
o India also expects a long-term growth in radiotherapy demand. Currently, radiotherapy is more
prominent in the private-sector, but it in the long-term the public sector will increase its investment.




CAGR of 7.3%     
until 2029
Up to 60% of cancer patients need
radiotherapy solutions. However, around
half of them are unable to access it. The
different states of development between
regions are key determinants to access rates
to radiotherapy solutions.
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Sources: Elekta’s Annual Report and Website; Grandviewresearch
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MARKET OVERVIEW | COMPETITIVE LANDSCAPE
Pursuit of the best cost-effective solutions that
could offset structural differences between
countries and regions.
Constant search for innovation (e.g., current
pandemic enhanced the importance of remote
monitoring and maintenance).
Acquisitions and partnerships play a key
role on differentiation and market share
gains.
Elekta’s main competitor is Varian but emergent markets dominance could offset discrepancies 
MARKET COMPETITIVE DYNAMICS
5 FORCES OF PORTER
Attracting and retaining the most qualified
employees
Companies must ensure that their products
are reimbursed as much as possible.
Protection of patients to maintain value














1 Competition in the industry       ►
2 Potential of new entrants           ►
3 Power of suppliers                     ►
4 Power of customers                  ►
5 Threat of substitute products   ►
➢ Competition based on R&D investment, cost-
efficiency and after-market services;
➢ Only Varian has an overlap with Elekta’s product
portfolio but there are significant number of
companies which address specific segments;
➢ High capital needs, strong and consolidated
companies within the market, existence of patents
and regulation complexity could strongly harm the
entrance of new competitors;
Low   Moderate   High
➢ In general, there is a wide range of suppliers which
cover raw materials and principal components needs,
implying lower bargaining power;
➢ However, some specific materials only provided by
few suppliers (Elekta’s MRI) increase their power;
➢ Prevalence of long-term contracts allied with high
customization pattern enhances the importance of
negotiation. Usually, the manufacturers have to adjust
the given solution in order to fulfill the customer
needs;
➢ High investment in R&D could imply short product
life-cycles, however long-term contracts secure
customer loyalty, thus diminishing this threat.
Papers, peer reviews and clinical data are
important to attract customers
Supremacy of service revenues as
companies try to maximize clients’ loyalty
and recurrent revenues by ensuring
maintenance and support services
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o Elekta is a key player of cancer treatment
equipment distinguished by its efficiency
o The company has reached leading position in
China and strong market share positions in
Americas (21%), EMEA (43%) and Asia
Pacific (40%)
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
o Free Cash Flow generated by the company has
been stable over the past few years
o Moreover, Cash Flow from Operating Activities
has ranged in the last three years between SEK
1000M and SEK 2400M
INVESTMENT THESIS| DEAL RATIONALE & VALUE CREATION STRATEGIES
o Elekta’s history is highly influenced by strategic
acquisitions that have allowed Elekta to widen
its portfolio, differentiate its products from the















Sizeable and Growing Market
o Optimistic radiotherapy industry growth
prospects over the next 5 years, since cancer
incidence is increasing all over the world, with
most markets currently underserved
o Governments are willing to allocate more money
in cancer care, as well as private sector
Accelerating Market Growth 
o MR-Linear Accelerators are set to continue to revolutionize radiotherapy. Therefore,
this market is expected to grow 20% a year. Elekta AB, being the major player in this
segment is well positioned to capitalize on this growth. Moreover, Elekta’s investment
in R&D will be key to consolidate its market position, by offering customized products
that are a key competitive advantage
o MEA and APAC markets are currently underserved, and the trend does not favour
them, since both will have the higher growths of cancer incidence (%) until 2040. This
creates an opportunity for ELEKTA to expand and consolidate its leadership
position in these regions: by taking advantage of its current brand reputation and by
leveraging its geographic presence through the acquisition of an APAC distributor
o Elekta will try to consolidate its position in the remaining markets. The South American
market is currently underserved, but its political and economical unstable climate are

























o Leverage competitive position by acquiring consolidated companies that broaden
Elekta’s product portfolio and are also in line the company’s high standard of precision
and efficiency. In line with internationalization, the acquisition of strategic distributors
will play a key role in Elekta’s short-term strategy. The company might also acquire





o Enhance transformation program pillars and exploit further improvement opportunities.
Continue investment in R&D, reduce COGS and SG&A by leveraging on digitalization
initiatives (remote services, cloud computing) and consolidate lower-cost
manufacturing solutions (replicate Harmony’s cost structure)
Software Distributors Proton Solutions
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Sources: Interview with Investor Relations
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Elekta has a variety of compelling value creation strategies that can enhance its key player position 
Founded in 2003, Micropos develops medical
devices for high precision 4D therapy. The
company manufactures an accessory for radiation
therapy machines to increase the precision and
efficiency of prostate cancer treatment.
Elekta would try to expand the 4D functionalities to
other types of cancers and leverage
hypofractionation (more precision, treatment in




































Notes: 1) Not included in Investment Case
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Elekta’s Buy & Build targets will contribute to strengthen Elekta’s position
Sources: HCG, IBA and Micropos’ websites, Reuters
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IBA (Ion Beam Applications) was founded in 1986,
from the Catholic University of Louvain-la-Neuve’s
Cyclotron Research Center (Belgium). Although its
primary emphasis started to be medical imaging, the
company moved its focus to proton therapy.
By acquiring one of the key players in the proton
therapy segment, Elekta will be well positioned to
capitalize on the proton therapy market’s growth
and consolidate its position as a global leader in the
radiotherapy segment.
Founded in 1989, Healthcare Global Enterprises is
one of the largest cancer care provider in India,
having a network of over 20 cancer centers spread
across India. Currently employs almost 6,000
people.
The acquisition of Healthcare Global Enterprises is
a major opportunity for Elekta’s expansion in
India and Africa, as it is a key distributor in the
market, since it already operates in both locations,
enhancing Elekta’s internationalization strategy.
Sales growth (proton solutions contributing with 23%);
Expand Elekta’s portfolio to cover all segments
radiotherapy market;
Increase worldwide proton market share.
Sales growth (across all Elekta’s product
portfolio);
Strengthen competitive position in APAC and
in Africa regions (more predominance in APAC).
Implement this feature in Elekta´s different
solutions portfolio in a medium/long term
perspective – apply to different cancers.






































The financials compromise the success of this
acquisition thus it was excluded from our forecast.
Free Cash Flow (M SEK) 2018 2019 2020 2021F 2022F 2023F 2024F 2025F CAGR 
20-25F
EBITDA 2,520 2,616 2,921 3,088 4,445 5,449 6,065 6,778 18.3%
Adjustments:
Change in Net Working Capital 1,665 -265 -1,212 218 -542 -920 -117 -216
Tax -203 -197 -184 -203 -409 -514 -574 -659
Maintenance Capex -816 -659 -762 -1,759 -2,238 -2,764 -3,116 -3,488
%revenues -7.1% -4.9% -5.2% -11.9% -9.9% -10.1% -10.5% -10.8%
Acquisition Capex - - - - -3371 -1943 - -
Cash flow before financing 
(Free cash flow - FCF)
3,166 1,495 763 1,345 (2,115) (693) 2,258 2,415 25.9%
%Growth (53%) (49%) 76% (257%) 67% 426% 7%
FCF (excl. acquisition 
capex)
3,166 1,495 763 1,3445 1,256 1,250 2,258 2,415 
• FCF excluding acquisition capex strengthens from
2020 to 2025 – growing at a CAGR of 25.9% and
reaching SEK 2,415M at exit. In 2022F and 2023F it
decreased, mainly attributable to the acquisitions of
IBA and HCG and variations of change in NWC;
o Elekta’s EBITDA will increase from SEK 2,921M in
2020 to SEK 6,778M in 2025, corresponding to a
CAGR of 18.3%. Its main drivers were HCG and
IBA acquisitions and organic growth;
BUSINESS PLAN | FINANCIALS FORECAST – FREE CASH FLOW
Robust cash flow generation driven by a solid EBITDA growth 
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FCF vs FCF excl Acquisition CAPEX FCF Breakdown
6
• Change in NWC will be positive in 2021F mainly
because of Covid-19 effects (increased average
payable/collection period). From this point onwards
it will come back to 2019 and 2020 values (being
less variable than it used to be);
2
• Tax includes tax shields from D&A and deductible
interest expenses assuming a 24% income tax.
3
• The acquisition of IBA and HCG in 2022F and
2023F respectively, represents a considerable cash















2018 2019 2020 2021F 2022F 2023F 2024F 2025F
Cash flow before financing (Free cash flow - FCF)










 EBITDA Change in NWC CAPEX FCF
• Maintenance Capex will range between 10-12% of
revenues based on forecasted Total Fixed Assets
and acquisitions of IBA and HCG.
4
4
o The Gross Profit can be divided
into revenues growth and gross
margin improvement;
o Revenues will increase over the
investment period from 14,601M to
32,408M due to the implementation of
the value creation strategies, leading
to an impact of 3,562 in EBITDA;
o Gross margin will improve from
42.6% (2020) to 44.6% (2025) due to
economies of scale and the
acquisition of HCG, leading to an
impact of 633M in EBITDA.
BUSINESS PLAN | FINANCIALS FORECAST – EBITDA BRIDGE
EBITDA will double until 2025 due to an increase of revenues and improvement of margins
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o The Covid-19 pandemic enhanced a
continuation of operational
improvements (digitalization, reduction
of travelling) that will drive the
reduction of these costs’ weights on
revenues;
o The integration of HCG and IBA will
somewhat offset these improvements,
as both companies have lower margins,
compared to ELEKTA, leading to a
negative impact of EBITDA margin of
338M.
EBITDA GROWTH DRIVERS1
Gross Profit EBITDA Margin
EBITDA GROWTH BRIDGE
Organic Growth
o Elekta will continue to develop
and enhance all its radiotherapy
solutions, however, MR-Linacs
and OIS will have the most
significant growths, as their
respective markets will increase
significantly over the next years;
o As a result, organic growth will
add SEK 1,272M to Elekta’s
EBITDA.
o As the market leader of proton
therapy, IBA is expected to
contribute with an additional SEK
1,542M to Elekta’s EBITDA over
four years, helping Elekta consolidate
its position as a leader in
radiotherapy.
o The acquisition of HCG will help
Elekta boost its revenues in all its
radiotherapy solutions in APAC and
some African regions. Consequently, it
is projected that Elekta’s EBITDA is
increased by SEK 1,044M.
IBA & HCG 
MSEK MSEK
BUSINESS PLAN | MANAGEMENT PACKAGE
MANAGEMENT PACKAGE
Management incentive package contains sweet equity, a bonus payment and a PSU’S plan
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PSU'S PLAN 2021E 2022E 2023E 2024E 2025E
% of sweet equity 0.50% 0.50% 0.75% 0.75% 1%
If Gross Profit and EBITDA are met at 100%
Gustaf Salford 0.27% 0.27% 0.40% 0.40% 0.54%
Johan Adebäck 0.11% 0.11% 0.16% 0.16% 0.21%
Paul Bergström 0.06% 0.06% 0.10% 0.10% 0.13%
Jonas Bolander 0.06% 0.06% 0.10% 0.10% 0.13%
If Gross Profit and EBITDA are met at 85%
Gustaf Salford 0.16% 0.16% 0.24% 0.24% 0.32%
Johan Adebäck 0.06% 0.06% 0.10% 0.10% 0.13%
Paul Bergström 0.04% 0.04% 0.06% 0.06% 0.08%
Jonas Bolander 0.04% 0.04% 0.06% 0.06% 0.08%
VESTING RULES 2021E 2022E 2023E 2024E 2025E
Final Sweet Equity Stake 15.0%
% Sweet Equity Vested 
per year
10% 25% 40% 80% 100%
Vested Equity Stake 1.50% 3.75% 6.00% 12.00% 15.00%
Management proceeds 74 658 1,638 4,175 6,681
Gustaf Salford 43 383 954 2431 3890
Johan Adebäck 14 125 311 793 1269
Paul Bergström 8 75 187 476 761
Jonas Bolander 8 75 187 476 761
PSU’S PLAN
A long-term incentive based on performance-vested shares contingent
upon achieving EBITDA and Gross Profit annual levels. The promised number
of shares are in line with the additional % of sweet equity defined on the
table to the right and will be split across management considering their entry
equity - if MM is lower than 2.50x they will not be rewarded.
3
Total Remuneration Bonus Payment
Gustaf Salford 15027 2216                                                 
Johan Adebäck 4901 875                                                
Paul Bergström 2940 525                                              
Jonas Bolander 2940 525                                                
TOTAL 25809 4141
In 2021, an immediate bonus payment will be paid to management, equal to
25% of their fixed annual salary amount. This payment will leverage
management’s motivation in the current pandemic context.
BONUS PAYMENT 2
25%
PARTICIPATION IN SWEET EQUITY
Managers will be required to invest twice its total annual salary in exchange
for a 15% equity stake which will be vested accordingly with the table.
The four members of the management team will have different equity stakes
(accordingly with their salaries and positions):
1
• Gustaf Salford will invest SEK 30.05M and receive 58% of sweet equity;
• Johan Adebäck will invest SEK 9.80M and receive 19% of sweet equity;
• Paul Bergström and Jonas Bolander will invest SEK 5.88M each and 
receive 11% of sweet equity.
1
3










EXIT & RETURNS | ENTRY MULTIPLE
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ENTERPRISE VALUE (M SEK)
DCF – EXIT MULTIPLE METHOD
o This DCF is based on an EV/EBITDA multiple
of 13.13x used to compute the terminal value.
o To discount the FCF, it was used a WACC of
6.64%, which is decomposed on Appendix X
o This valuation was not included in the final




o Considering the same list of 6 comparables, a
valuation through one-year forward
EV/EBITDA multiples was computed, arriving




DCF – GORDON’S GROWTH
o The DCF using Gordon’s growth model was
performed with a terminal growth rate (TGR)
of 2.5% (in line with market prospects – e.g.
increase of cancer incidence).
o It was not included in the final EV as it is
mainly explained by the terminal value




o Considering a qualitative and quantitative
analysis (i.e. similar EBITDA margin and capital
structure) it was possible to list 6 comparables.
o Using one-year forward P/E multiples, the
minimum value was 22.71x while the




o This valuation methodology was computed
based on past transactions in the cancer
care industry.
o It was possible to verify that there is recurring
discrepancies in the multiples’ value, ranging




o A 10-year cycle adjustment was made for
both multiples used in the comparables
analysis to eliminate one-time events.
o In general, there has been a multiples’






Considering different methodologies, an EV/EBITDA of 13.13x and an EV of SEK 38,339M was arrived
Sources and Uses of Funds:
Sources of Funds
▪ They are distributed between Debt (5x EBITDA – 14,605M) and Equity (8.8x EBITDA – 25,651 M);
▪ Total Debt is allocated among two tranches (A and B) - Term A amortized senior Debt of 2,921M – 1x
EBITDA and Term B bullet payment senior Debt of 11,684M – 4x EBITDA.
▪ Equity is divided in FRI (25,307M – 8.7x EBITDA) and Ordinary Equity (344M – 0.1x EBITDA).
Uses of Funds
▪ Total Uses of funds corresponds to SEK 40,256M, distributed into EV (38,339M – 95%) and Fees
(1,917M – 5%);
Scenarios – Capital Structure:
▪ Scenario 1 was chosen in favor of number 2 and 3, as it constitutes a more conservative approach
(better Cash Cover, Interest Coverage and Debt/EBITDA), without compromising the minimum
threshold of the investor’s returns. In comparison with scenario 9, scenario 1 was chosen because it
presents better returns for investors.
EXIT & RETURNS | CAPITAL STRUCTURE
Sources of funds will be composed of 63.7% equity and 36.3% debt
























SOURCES & USES OF FUNDS1



















SCENARIOS – CAPITAL STRUCTURE
FINAL RATIONALE
Notes: 1) Including cash overfunding – used on acquisitions
SCENARIOS 1 2 3 9
Leverage 5.0x 6.0x 5.5x 4.5x
IRR 24.00% 25.74% 24.83% 23.23%
MM 2.93x 3.14x 3.03x 2.84x
Cash Cover
SCENARIOS Term A Term B Term C 2021 2022 2023 2024 2025
1 1.0x 4.0x 0.0x 1.4x 1.5x 1.5x 2.1x 2.3x
2 1.0x 5.0x 0.0x 1.2x 1.4x 1.4x 1.9x 2.1x
3 1.0x 4.5x 0.0x 1.3x 1.4x 1.5x 2.0x 2.2x
9 1.0x 3.5x 0.0x 1.4x 1.6x 1.6x 2.2x 2.4x
EXIT & RETURNS| EXIT WATERFALL & CREDIT STATISTICS
The fund’s investors will have a return of 3.14x, corresponding to an IRR of 25.7% 
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EXIT WATERFALL BRIDGE
MSEK
The presented credit statistics imply that all covenants will be respected
(computed via conservative bank case) under the predicted investment case
scenario. Specifically, Cash Cover (excluding acquisitions) and Interest Cover will
start with 1.4x and 7.2x multiple, respectively, and will increase over the investment
period as the firm is more capable of paying debt obligations. Debt/EBITDA will start
at 4.6x in 2021 and will decrease to 1.8x at the year of exit due to Term Loan A
amortization and EBITDA increase. The cash amount was excluded from this analysis
since its value is abnormal due to overfunding.
Summary Credit Stats 2021F 2022F 2023F 2024F 2025F
Cash Cover 1.4x 1.5x 1.5x 2.1x 2.3x
Cash Covenant 1.0x 1.0x 1.0x 1.0x 1.0x
Interest Cover 7.2x 10.3x 11.9x 13.5x 16.5x
Interest Covenant 6.4x 7.5x 8.7x 9.4x 10.8x
Debt / EBITDA 4.6x 3.1x 2.5x 2.1x 1.8x
Leverage Covenant 5.1x 4.5x 3.8x 3.4x 3.0x
CREDIT STATISTICS
In 2025, management receives proceeds of SEK 6,681M, corresponding
to a MM of 129.4x and an IRR of 164.5% (PSU Plan included);
Institutional investors receive, in the exit year (2025), SEK 75,037M,
which translates in a return of 2.93x (MM) and an IRR of 24.0%
Returns 2021F 2022F 2023F 2024F 2025F
Management Exit 
Proceeds
74 658 1,638 4,175 6,681
Management Entry Equity 52 52 52 52 52




32,491 45,842 56,384 65,139 75,037
Institutional Investor 
Equity
25,599 25,599 25,599 25,599 25,599
Institutional Returns 1.27x 1.79x 2.20x 2.54x 2.93x
IRR 24.0%
In 2025, a combined value (EV + Cash) of SEK 94,132M will be distributed into debt
repayments, investors and managers. At exit, debt value will be SEK 12,414M, since it
is still left to repay SEK 730M of Term Loan A (amortized over 6 years) and the total of
Term Loan B (because it is amortized only at year seven).
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STRATEGIC SALE IPOSECONDARY SALE
EXIT OPTIONS & DUE DILIGENCE | EXIT OPTIONS & TARGET BUYERS
A strategic sale implies that another major player







More expensive process – High
transaction costs (e.g. underwriter fees are
the largest)
Access to capital markets, increasing
significantly the number of potential buyers
comparing with the other exit solutions.
Because such acquisition would bring
benefits for the acquirer (i.e., synergies), it
is likely that the transaction value would
include a premium, increasing the returns
for the fund;
The feasibility of this option is highly
dependent on finding a suitable target
acquirer. In this particular case, because
Elekta AB is one of the biggest players in
radiotherapy, a target buyer would
probably have to come from another
sector closely related to radiotherapy;
Moreover, a strategic sale is usually slower
than a secondary sale. Furthermore, strategic
sales are losing popularity in this sector,
having decreased from 40% to 33% in 2018.
In the last years, PE exit through IPO’s in
healthcare industry were mainly linked to
biopharma smaller-stage companies.
It has become more frequent following the PE
sector increasing trend. The Exit Value of
Healthcare PE industry increased in 2019 to
$40.8B, compared with $31.6B in 2018,
moreover, secondary sale transactions
represented 53% in 2019;
ELEKTA is an attractive buyout target –
healthy CF and room to become the market
leader of radiotherapy industry (high growth
potential);
Industry’s strong returns allied and
resilience at any stage of the economic
cycle. In addition, this strategy is faster than
the alternatives;
Increasing interest from strategic buyers
lead to higher entry valuations which are
unattractive to potential PE buyouts;
Dependent on market conditions and
specific timings that could harm fund’s exit
and returns.
Sources: Bain & Company Report “Healthcare Exits”
Typically, the fund is not able to sell all 
its equity position, thus increasing the 
overall risk of the exit (i.e. subject to post-
IPO market reaction and loss of control)
INDIVIDUAL SECTION
MARKET OVERVIEW | PROTON THERAPY
PROTON SOLUTIONS vs. TRADITIONAL RADIOTHERAPY
o Radiotherapy’s origins can be traced
back to the final years of the XIX
century, when Wilhelm Rontgen
discovered the X-rays. Soon after, it was
found that X-rays could be used to
fight certain diseases, as they are able
to destroy [infected] tissues;
o Radiotherapy has evolved significantly
since then. One of the most important
steps was the development of linear
accelerators: These machines enable
the projection of external x-ray beams
to the tumors with high-precision;
o However, some radiotherapy treatments
use internal sources of radiotherapy (ex:
brachytherapy), where the radiation
comes from a medical equipment that is
inserted inside the body, near the tumor;
o Even though radiotherapy has come a
long a way, one cannot forger that as x-
rays are used to destroy cancerous
cells, it is almost impossible to avoid
damaging tissue.
o As survival rates from cancer have
been increasing significantly, new
concerns have been raised about
side-effects of treatments and the
quality of life that survivors can expect;
o These concerns have not only resulted
in optimizing palliative cares, but also in
looking for not so invasiveness
treatments. Proton therapy solutions
belong to the latter category;
o Like many traditional radiotherapy
treatments, proton solutions use
external beams. The difference comes
from the nature of protons and how they
travel to the infected tissue;
o By using a synchrotron, protons are
accelerated, generating high levels of
energy that make the protons travel to
the tumor, destroying it like X-ray beams
does. The main difference is that
protons do not travel further than the
target, not damaging healthy tissue.
This is not the case for x-ray beams.
Proton therapy is set to revolutionize radiotherapy in the next few years
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2020 2021 2022 2023 2024 2025
PROTON THERAPY KEY FACTS
KEY PLAYERSMAIN DRIVERSEND MARKET
➢ Reduce side effects;
➢ Increase precision;
➢ Reduce expending on 
palliative cares;
➢ Increase survival rates 




















































o In line with the market characteristics, Elekta sets
essential focus on R&D and its acquisition strategy.
By acquiring companies, usually start-ups, the
company ensures a quicker way to differentiate from
its competitors;
o Recent acquisition of PalabraApps, SmartClinic and
Kaiku Health strengthens Elekta’s digitalization
portfolio;
o 15% of net sales is done through distributors. Elekta
has companies in 40 countries and sells in 220
countries. In countries with distributors, the
distributors are usually getting the service contracts;
o Optimism in the proton solutions’ market creates
room for a potential acquisition in this segment.
14.9% CAGR
2020 - 2030
o With cancer incidence rates growing, with structural differences between regions and countries
increasing and with the current pandemic outbreak, the importance of digitalization has been
enhanced, implying that remote services and monitoring should lead the way on innovations;
o In line with past acquisitions of distributors, Elekta must ensure close relationships and increase its
credibility in the different regions where the company sells. After laying pillars in a specific region
(i.e. increase the number of Linacs used in those regions to around 35-40) a strategic acquisition
of a distributor could be efficient to increase margins;
o Potential of proton solutions’ market, in terms of benefits and efficiency for cancer treatment, could
be seized by Elekta by acquiring a promising company in this specific market.
✓ Increase the weight of the inorganic contribution to the revenues between 2020 and 2025;
✓ Reinforce internationalization’ objectives through acquisition of strategic distributors in APAC
region;
✓ Incorporate new solutions, software functionalities or services that could increase its





EXPECTED GROWTH FOR 
PROTON SOLUTIONS’ 
MARKET:
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Elekta’s Buy & Build strategy is the key determinant for Elekta’s and other strategies success
Acquisition of IBA – Ion Beam
Application (Proton key player) in
2022
Acquisition of Healthcare Global
Enterprise (Distributor in India) in
2023
o Achieve an inorganic contribution for
revenue of 18% between 2021-2025;
o Become a major player in the proton
therapy market – acquisition of IBA;
o Reach more than SEK 4,000M of proton
revenues by 2025, through IBA;
o Reach more than SEK 1,850M revenues by
2025, through HCG.
Both acquisitions will be paid full in cash,
considering the substantial cash balance













































o Founded in 1989, Healthcare Global Enterprises is one of the largest cancer
care provider in India, having a network of over 20 cancer centers spread
across India. Currently employs almost 6,000 people;
o The company also operates in fertility treatments, providing reproductive
medicine services, under brand Milann, with a network of 8 fertility centers;
o The company has end to end capabilities in precision medicine under brand
Strand;
o Recently expanded its operations to Africa, through an acquisition of CCK;
o The acquisition of Healthcare Global Enterprises represents a major opportunity
for Elekta’s expansion in India and Africa, this cancer care distributor is a key
player in the market, since it already operates in both locations and has
valuable markets insights that Elekta can benefit from;
o Elekta signed a licensing agreement with HCG (Elekta will install Linacs, MR-
Linac and also its OIS solutions - MOSAIQ and Monaco), meaning that it is
already building a relationship with this player. Moreover, when a country gets
to 35-40 Linacs, Elekta tends to acquire its regional distributor.
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
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o IBA (Ion Beam Applications) was founded in 1986, as a result of a spin-off
from the Catholic University of Louvain-la-Neuve’s Cyclotron Research
Center (Belgium);
o Although its primary emphasis started to be medical imaging, the company
soon moved its focus to radiotherapy and proton therapy;
o In the following years, IBA has become a major player in the field, through the
development of innovative solutions and the acquisition of other companies;
o In 2016, 50,000 people have been treated with IBA’s proton solutions.
o Elekta might replicate its brachytherapy market entry approach by acquiring a
consolidated key player in the proton therapy market – IBA – the market leader
in proton therapy;
o It has a higher market value than brachytherapy, MR-linear accelerator and
stereotactic radiosurgery, being its CAGR of 15% until 2030;
o Furthermore, in 2017, IBA and Elekta agreed to work jointly in the development
of OIS and in the sales and marketing of both companies.
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
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o Proton Therapy – IBA manufactures and sells proton solutions to both
hospitals and clinics to treat many kinds of oncologic diseases.
o Dosimetry & Quality Assurance – This department is responsible for the
development of software and equipment maintenance, which assures that
solutions keep up with the standards of high precision medicine;
o Radiopharma Solutions – IBA manufactures and sells nuclear medicine
solutions for medical diagnosis;
o Industrial Solutions - IBA also designs solutions for sterilization of
medical devices, cargo screening and other industrial applications.























2016 2017 2018 2019
Revenues (M SEK) and EBITDA margin (%)
Total Revenue EBITDA Margin
INVESTMENT THESIS | FINANCIALS FORECAST – IBA
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Synergy drivers
o IBA has three main revenues’ segments: proton
therapy, other accelerators (nuclear medicine
diagnosis solutions) and dosimetry (OIS and
maintenance). The first two segments have been, to
some degree, erratic, with dosimetry being the most
constant. This being said, it would be expected
dosimetry to have its revenues doubled and proton
therapy and other accelerators to increase at a
lower rate. Yet, with Elekta’s acquisition of IBA, the
“Other Accelerators” segment will be discontinued.
As the investment in proton therapy will be more
significant, the revenues breakdown will change,
resulting in slightly higher revenues for IBA;
o IBA’s gross margin will improve slightly, as the
“Other Accelerators” have lower margins;
o SG&A would be projected to stabilize at 20.3% of
revenues. However, some processes will be made
jointly (i.e. a same person can sell proton solutions
and Linacs). Consequently, it can decrease to 17%.
Therefore, EBITDA margin can go up to 11.7%,










PRE-SYNERGIES Income Stat. M (SEK) 2019 2020 2021F 2022F 2023F 2024F 2025F
Total Revenue 2,879 2,699 3,034 3,074 3,156 3,481 3,831
Proton Therapy 1,613 1,575 1,860 1,800 1,800 2,100 2,400
Other Accelerators (radio-diagnosis) 717 574 574 574 631 631 631
Dosimetry 548 550 600 700 725 750 800
Gross Profit 949 945 1,092 1,122 1,168 1,296 1,426
%Revenues 33.0% 35.0% 36.0% 36.5% 37.0% 37.2% 37.2%
SG&A (incl. D&A) -630 -580 -615 -624 -640 -706 -777
%Revenues 21.9% 21.5% 20.3% 20.3% 20.3% 20.3% 20.3%
R&D (incl. D&A) -316 -296 -333 -338 -347 -382 -421
% Revenues 11.0% 11.0% 11.0% 11.0% 11.0% 11.0% 11.0%
Cancelling D&A 131 107 113 107 102 104 105
Other Operating Income (Expense) 55 -13 -15 -30 -31 -34 -38
Normalized EBITDA 189 162 241 237 251 276 294
EBITDA Margin 5.6% 6.0% 8.0% 7.7% 8.0% 7.9% 7.7%
POST-SYNERGIES Income Stat. M (SEK) 2019 2020 2021F 2022F 2023F 2024F 2025F
Total Revenue 2,879 2,699 3,034 3,074 3,302 3,887 4,144
Proton Therapy 1,613 1,575 1,860 1,800 2,100 2,700 3,000
Other Accelerators (radio-diagnosis) 717 430 574 574 401 287 143
Dosimetry 548 550 600 700 800 900 1,000
Gross Profit 949 945 1,092 1,137 1,238 1,466 1,563
%Renevues 33.0% 35.0% 36.0% 37.0% 37.5% 37.7% 37.7%
SG&A (incl. D&A) -630 -580 -615 -605 -610 -684 -704
%Revenues 21.9% 21.5% 20.3% 19.7% 18.5% 17.6% 17.0%
R&D (incl. D&A) -316 -296 -333 -338 -363 -427 -455
% Revenues 11.0% 11.0% 11.0% 11.0% 11.0% 11.0% 11.0%
Cancelling D&A 131 107 113 104 105 112 111
Other Operating Income (Expense) 55 -13 -15 -23 -24 -29 -31
Normalized EBITDA 189 162 241 275 345 438 484
EBITDA Margin 0.0% 6.0% 8.0% 9.0% 10.5% 11.3% 11.7%
INVESTMENT THESIS | INTERNATIONALIZATION
Emergent markets in APAC and replacement needs in Americas and EMEA will drive Elekta’s strategy
FUTURE STRATEGYCURRENT SITUATION
o Elekta’s revenues are similar across regions;
o MEA and APAC markets are currently underserved:
higher cancer incidence in these regions allied with
few therapy equipment availability leads to a global
shortage of Linacs of 10,000 units (e.g. China alone
is estimated to have a shortfall of over 5,000
systems);
o There is room to grow, even though ELEKTA has a
solid market share in EMEA and APAC - above 40%
in both regions. ELEKTA might consolidate its
position in Europe and Americas, while expanding















o Set long-term contracts with APAC
distributors, hospitals and clinics to
establish strong relationships (aftermarket
services will have a key role);
o Continuing to close deals and make more
partnerships with governments (ex: China,
India) to obtain (operating) licensing













N o Reach the revenues’ split (geographically) of 30%
in Americas; 33% in EMEA; and 37% in APAC;
o Increase geographical presence, brand
awareness and reputation among all continents;
o Increase total number of solutions manufactured
















✓ Increase global geographic presence;
✓ Increase APAC net sales performance in order to become the region that contributes the most to
Elekta’s revenues in the short-term, in line with the Buy and Build strategy – distributor acquisition
✓ Consolidate Elekta’s position as a leading manufacturer of radiotherapy equipment APAC markets;
✓ Increase total revenues from both solutions and services across all continents;
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o APAC expansion: this region will have 50% of worldwide cancer cases in 2040. Its solid market
share will enable Elekta to benefit from its current leadership reputation in future deals. Moreover,
the cancer healthcare system is expected to grow in large countries, like China and India which
have recently approved Elekta’s products commercialization. HCG acquisition (Indian distributor)
will reinforce APAC’s importance as a strategic region to be explored in nearby future;
o MEA expansion: cancer incidence will grow 50% up until 2040. HCG (Indian distributor) already
has distribution partnerships in Africa which enables Elekta to explore this underserved market in
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MR-Linacs market value ($M) 
INVESTMENT THESIS | ACCELERATING MARKET GROWTH
The increasing demand for MR-Linacs will meaningfully shape the radiotherapy market
FUTURE STRATEGYCURRENT SITUATION
o With this agreement, ViewRay will not be a major competitor of Elekta, but an ally. As both firms have
the know-how, there will be less competition in this stage and more entry barriers to potential
newcomers. This will make it easier for Elekta to succeed in this new market segment.
o In addition, by investing in ViewRay, Elekta ensures that both pioneers of MR Guided Radiation Therapy
will continue exploiting the market potential, thus driving the paradigm shift forward, as Elekta’s previous
CEO believed that MR-Linacs are set to be a major technology in radiotherapy;










































o The MR-Linac market was valued at 220 million
dollars in 2018 and it is estimated that it can grow at
an average of 20% a year until 2028, reaching 1,362
billion dollars in that same year;
o Elekta is the main producer of MR-Linacs - Elekta
Unity - which is considerable better than the product
offered by ViewRay, especially in terms of imaging;
o In December 2019, Elekta has reached an
agreement with ViewRay (second key player) in
which the company bought 9.9% of ViewRay’s
shares of common stock;
o In line with this agreement, a collaboration, focused
on promoting MR Linac’s technology and its benefits
for the clinicians and patients, was made. With this
partnership, Elekta will strength its position.
✓ Promote MR-Linacs as the future of precision in radiotherapy medicine;
✓ Increase the number of MR-Linacs produced, spreading the fixed cost base over a larger number of
produced units, increasing the profit margin;
✓ Continue to work on its brand reputation as a market leader / quality provider of radiotherapy solutions;
✓ Increase its market share position in the MR-Linacs market;
✓ Increase its revenues from aftermarket services related to the MR-Linacs.
o Increase available production capacity of
MR-Linacs;
o Prepare distribution channels to cope with
the increasing demand;
o Continue joint investigation and
collaboration with ViewRay in order to
achieve a higher cost efficiency (MR-
Linac) and to promote this innovative
radiotherapy solution.
o Increase MR-LINAC’s weight of total net
revenues to 7%;
o Produce and sell around 200 MR-LINAC’s until
2025;
o Improve market’s perception of the high-quality
of Elekta’s products portfolio.
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COGS Selling expenses Administrative expenses R&D expenses
INVESTMENT THESIS | OPERATIONAL IMPROVEMENTS
Operational improvements can create key competitive advantages for Elekta
FUTURE STRATEGYCURRENT SITUATION
o From 2015 (transformation program) the company
focus was to improve its internal operations and
strengthen its margins;
o Its main objectives were the availability to save
costs (COGS, SG&A), continuing to invest high in
R&D, M&A synergies acquisitions that would bring
value to the company;
o Digitalization of the company enabled Elekta to
share services internally, to increase the importance
of remote services (aftermarket) and to reduce
travel expenses;
o Elekta was able to increase its EBITDA margin. Its









































Eo Replicate Harmony’s cost structure (in
terms of production) into existent solutions;
o Set training programs to increase
workflows and facilitate restructuring of
operations;
o Set further digitalization processes ( remote
assistance and working);
o Streamline operations in SG&A (multi-
functions departments; enhance
digitalization of work).
o Total gross margin of 44.6% driven by economies
of scale in MR-Linac and replication of Elekta’s
Harmony cost structure in Linac solutions;
o EBITDA margin of 21% driven by reduction of
selling expenses’ weights to 8%;
o Increase EBIT by more than 2.3x also driven by
increase of revenues by 2.2x;
✓ Increase gross margin;
✓ Increase EBITDA margin;
✓ Consolidate lower-cost manufacturing solutions, such as the Elekta Harmony, without
compromising precision and efficiency;
✓ Reduce the weight of other operating costs such as SG&A.
o The 2015 transformation program resulted in a more optimized structure, contributing to Elekta’s
competitiveness. Consequently, further restructuring plans will be faced with much more
confidence and enthusiasm. The board will also be more optimistic about implementing measures
such as: remote assistance, remote-working – driven by Covid-19;
o Employees have been already embracing these changes positively and will continue to do so;
o Elekta has very recently launched a new solution – Elekta Harmony – with significant less costs
than other solutions. Elekta Harmony’s optimized gross margin makes the company optimistic
about further manufacturing developments that can improve existent solutions’ margins.
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1
Notes: 1) SG&A and R&D expenses include D&A
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
Gratitude for having worked with this group in an increasing healthcare PE market
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MASTER THESIS
PRIVATE EQUITY – IMPACT OF COVID-19 IN PE DEALS ON HEALTHCARE SECTOR  
INDIVIDUAL REFLECTION | 41212
I embraced this thesis with the main objectives of deepening my knowledge in Private Equity and taking advantage of the know-how of my 2 excellent partners, Henrique
and Gonçalo, to consolidate ideas, create new perspectives and develop my communication and attitude when working as a team. These challenges became more
complicated since, for extraordinary reasons, I had to join a part-time at Primark (5 hours a day) during the months of September, October and November. However, with
the precious help of Henrique and Gonçalo we managed to face this situation and I couldn't be more grateful for the continuous understanding and adaptability that the
group had. My attitude was always to contribute the best/most as possible and I believe we have managed to find a balance that has resulted in a work for which we are
all proud and excited to present. The company we chose, Elekta, increased the complexity of this thesis. The radiotherapy market is highly regulated and perhaps that is
why access to information is limited or dependent on substantial payments. Thus, it was a constant challenge, also considering our background (outside science), to
interpret trends and address Elekta's limitations (strategically and financially). Despite all these limitations, the feelings are of duty fulfilled and gratitude for having worked
with this group, and undoubtedly, my doors will be open for any opportunities in this exciting area of ​​Finance and in the healthcare sector.
In 2019, there were 313 PE deals linked to the healthcare sector, totaling $78.9 billion in disclosed value and it was possible to verify that the deal size has been
increasing over the last years, since 27 of those 313 deals were greater than $1 billion compared with 18 such deals in 2018. However, as in all industries, the covid-19
pandemic influenced the overall PE market. The complexity of the due diligence increased (time extension of the pandemic and the underlying impact on the
business model), there were more limitations in accessing debt financing and consequently the number of delays in negotiations increased. Nonetheless,
specifically in the healthcare sector, there was a clear rebound in many sectors since July with many investors pursuing attractive acquisition opportunities. In my
perspective, the resilience of this sector during the pandemic is explained mainly by the following factors:
The pandemic had a positive impact on healthcare digitalization, as companies were forced to progress faster solutions such as telemedicine and remote
services;
Aging and increasing population, magnifies growing incidence of chronic diseases (e.g. cancer) thus increasing the importance of creating efficient treatments;
In past recession, the healthcare sector showed resilience thus LP’s considered it to be an attractive opportunity to allocate the high amount of dry-powder
underlying the PE market.
Concluding, the healthcare PE activity should keep the increasing trend with AI, machine learning and Big Data as main growth drivers and more specifically, in the
radiotherapy market, investors should be highly focused in the Alternative Payment Model (US new reimbursement method that is being tested) as it could revolutionize the
overall reimbursement scope - instead of receiving reimbursement based on a fee for each service provided, the payment will be determined by the patient’s diagnosis and
include all radiation oncology services provided within a 90-day period, forcing clinics to use Hyperfractionation as they don’t get advantage from getting more sessions.
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Websites lead the path on finding information about ELEKTA / Radiotherapy Market
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